Interestingly, the 1 year secondary event‐free survival rates were 61.1% for the MC group and 35.4% in the control group, although this difference did not reach statistical significance ( p = 0.204). 44 MC is being employed as a cost‐effective and viable approach to rescue patients who have encountered relapse or are facing refractory neuroblastoma.
1
0.2040
0.2040